Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126552021 | 12655202 | 1 | I | 20160701 | 20160728 | 20160816 | 20160816 | EXP | IT-ASTRAZENECA-2016SE82641 | ASTRAZENECA | 63.00 | YR | F | Y | 0.00000 | 20160816 | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126552021 | 12655202 | 1 | PS | FASLODEX | FULVESTRANT | 1 | Intramuscular | U | U | 0 | INJECTION | ||||||||
| 126552021 | 12655202 | 2 | SS | PALBOCICLIB | PALBOCICLIB | 1 | Oral | 1875 | MG | Y | U | 0 | 125 | MG | CAPSULE | QD | |||
| 126552021 | 12655202 | 3 | C | NEBILOX | NEBIVOLOL HYDROCHLORIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126552021 | 12655202 | 1 | Breast cancer |
| 126552021 | 12655202 | 2 | Breast cancer |
| 126552021 | 12655202 | 3 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126552021 | 12655202 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126552021 | 12655202 | Neutropenia | |
| 126552021 | 12655202 | Off label use |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126552021 | 12655202 | 1 | 20160422 | 0 | ||
| 126552021 | 12655202 | 2 | 20160617 | 0 |